ZIA CP010131 04140 (ZIA) | |||
---|---|---|---|
Title | Second cancers following retinoblastoma | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Morton, Lindsay | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $431,359 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) Cancer Survivorship (100.0%) Chemotherapy (20.0%) Childhood Cancers (100.0%) |
Breast (15.0%) Melanoma (15.0%) Sarcoma (70.0%) |
||
Research Type | |||
Endogenous Factors in the Origin and Cause of Cancer Interactions of Genes and/or Genetic Polymorphisms with Exogenous and/or Endogenous Factors |
|||
Abstract | |||
The NCI has been studying the risk of second cancer in relation to treatement a cohort of 2,000 - one year survivors of retinoblastoma (RB) diagnosed 1914-2006, many of whom were treated with radiation. Radiotherapy and chemotherapy resulted in greater risks of all second cancers, especially bone cancer, compared to radiotherapy alone. The purpose of this Retinoblastoma Biomarker Study is to determine if specific mutations in the RB1 gene may be associated with increased risk for development of a second cancer (sarcoma or melanoma), and to continue to determine second cancer risk. Additional exomic and genomic sequencing is also in progress. Annual searches of the National Death Index are performed periodically to determine mortality in the cohort for the purpose of updating vital status and obtaining cause of death in the cohort. |